DaVita (NYSE:DVA) Reaches New 1-Year Low After Analyst Downgrade

Shares of DaVita Inc. (NYSE:DVA) hit a new 52-week low during mid-day trading on Tuesday after Truist Financial lowered their price target on the stock from $140.00 to $128.00. Truist Financial currently has a hold rating on the stock. DaVita traded as low as $111.43 and last traded at $113.19, with a volume of 213842 shares traded. The stock had previously closed at $113.94.

Several other analysts also recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Barclays cut their price objective on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Bank of America lowered their price target on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday, September 10th. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, UBS Group reaffirmed a “buy” rating on shares of DaVita in a research note on Monday, December 15th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $145.60.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its holdings in DaVita by 2.0% during the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after purchasing an additional 32,358 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of DaVita by 8.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock worth $144,230,000 after buying an additional 88,061 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of DaVita by 109.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after acquiring an additional 289,725 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of DaVita by 138.5% in the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock valued at $61,502,000 after acquiring an additional 269,015 shares during the last quarter. Finally, KBC Group NV increased its position in shares of DaVita by 38.7% in the second quarter. KBC Group NV now owns 374,749 shares of the company’s stock valued at $53,383,000 after acquiring an additional 104,554 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Performance

The company has a market cap of $8.00 billion, a P/E ratio of 11.66, a P/E/G ratio of 0.70 and a beta of 0.99. The business’s 50-day moving average price is $118.54 and its 200 day moving average price is $129.64.

DaVita (NYSE:DVA) last released its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm earned $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.